The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial.

Thazhath SS, Marathe CS, Wu T, Chang J, Khoo J, Kuo P, Checklin HL, Bound MJ, Rigda RS, Crouch B, Jones KL, Horowitz M, Rayner CK

Diabetes15 Oct 2015Cited by 72 (Europe PMC)

PMID26470783DOI10.2337/db15-0893PepBankPUB-26470783

Source link PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialMechanism
In healthy subjects and patients with type 2 diabetes, exenatide reduced duodenal pressure waves compared with saline.
In plain wordsExenatide reduced intestinal pressure waves compared with saline in healthy people and people with type 2 diabetes.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseDuodenal pressure waves
Study
n = 20
Comparator
saline
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
7.5 μg · intravenous · -30 to 240 minAs given in this study (human).
Source sentences
Summary
In both groups, duodenal pressure waves and antegrade flow events were fewer, and transit was slower with exenatide, as were the areas under the curves for serum 3-OMG and blood glucose concentrations.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 10 healthy subjects and 10 patients with type 2 diabetes received intravenous exenatide (7.5 μg) or saline (-30 to 240 min) in a double-blind randomized crossover design.
Report a problemFND-2647078301
02HumanRandomized controlled trialMechanism
In healthy subjects and patients with type 2 diabetes, exenatide reduced antegrade flow events compared with saline.
In plain wordsExenatide reduced forward intestinal flow events compared with saline in healthy people and people with type 2 diabetes.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseAntegrade flow events
Study
n = 20
Comparator
saline
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
7.5 μg · intravenous · -30 to 240 minAs given in this study (human).
Source sentences
Summary
In both groups, duodenal pressure waves and antegrade flow events were fewer, and transit was slower with exenatide, as were the areas under the curves for serum 3-OMG and blood glucose concentrations.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 10 healthy subjects and 10 patients with type 2 diabetes received intravenous exenatide (7.5 μg) or saline (-30 to 240 min) in a double-blind randomized crossover design.
Report a problemFND-2647078302
03HumanRandomized controlled trialMechanism
In healthy subjects and patients with type 2 diabetes, exenatide slowed intestinal transit compared with saline.
In plain wordsExenatide slowed intestinal transit compared with saline in healthy people and people with type 2 diabetes.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSmall intestinal transit
Study
n = 20
Comparator
saline
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
7.5 μg · intravenous · -30 to 240 minAs given in this study (human).
Source sentences
Summary
In both groups, duodenal pressure waves and antegrade flow events were fewer, and transit was slower with exenatide, as were the areas under the curves for serum 3-OMG and blood glucose concentrations.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 10 healthy subjects and 10 patients with type 2 diabetes received intravenous exenatide (7.5 μg) or saline (-30 to 240 min) in a double-blind randomized crossover design.
Report a problemFND-2647078303
04HumanRandomized controlled trialMechanism
In healthy subjects and patients with type 2 diabetes, exenatide reduced serum 3-OMG area under the curve compared with saline.
In plain wordsExenatide reduced serum 3-OMG exposure compared with saline in healthy people and people with type 2 diabetes.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSerum 3-OMG area under curve
Study
n = 20
Comparator
saline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
7.5 μg · intravenous · -30 to 240 minAs given in this study (human).
Source sentences
Summary
In both groups, duodenal pressure waves and antegrade flow events were fewer, and transit was slower with exenatide, as were the areas under the curves for serum 3-OMG and blood glucose concentrations.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 10 healthy subjects and 10 patients with type 2 diabetes received intravenous exenatide (7.5 μg) or saline (-30 to 240 min) in a double-blind randomized crossover design.
Report a problemFND-2647078304
05HumanRandomized controlled trialEfficacy outcome
In healthy subjects and patients with type 2 diabetes, exenatide reduced blood glucose area under the curve compared with saline.
In plain wordsExenatide reduced blood glucose exposure compared with saline in healthy people and people with type 2 diabetes.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBlood glucose area under curve
Study
n = 20
Comparator
saline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
7.5 μg · intravenous · -30 to 240 minAs given in this study (human).
Source sentences
Summary
In both groups, duodenal pressure waves and antegrade flow events were fewer, and transit was slower with exenatide, as were the areas under the curves for serum 3-OMG and blood glucose concentrations.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 10 healthy subjects and 10 patients with type 2 diabetes received intravenous exenatide (7.5 μg) or saline (-30 to 240 min) in a double-blind randomized crossover design.
Report a problemFND-2647078305
06HumanRandomized controlled trialMechanism
In healthy subjects and patients with type 2 diabetes, insulin concentrations with exenatide were initially lower and subsequently higher than with saline.
In plain wordsCompared with saline, exenatide initially lowered and later raised insulin concentrations in healthy people and people with type 2 diabetes.
Peptide
Exenatide (exendin-4)
Outcome
MixedInsulin concentrations
Study
n = 20
Comparator
saline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
7.5 μg · intravenous · -30 to 240 minAs given in this study (human).
Source sentences
Summary
Insulin concentrations were initially lower with exenatide than with saline and subsequently higher.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 10 healthy subjects and 10 patients with type 2 diabetes received intravenous exenatide (7.5 μg) or saline (-30 to 240 min) in a double-blind randomized crossover design.
Report a problemFND-2647078306
07HumanRandomized controlled trialSafety outcome
In healthy subjects and patients with type 2 diabetes, exenatide increased nausea compared with saline.
In plain wordsExenatide increased nausea compared with saline in healthy people and people with type 2 diabetes.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseNausea
Study
n = 20
Comparator
saline
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
7.5 μg · intravenous · -30 to 240 minAs given in this study (human).
Source sentences
Summary
Nausea was greater in both groups with exenatide, but suppression of small intestinal motility and flow was observed even in subjects with little or no nausea.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 10 healthy subjects and 10 patients with type 2 diabetes received intravenous exenatide (7.5 μg) or saline (-30 to 240 min) in a double-blind randomized crossover design.
Report a problemFND-2647078307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT07297238

Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.

Jinling Hospital, Chinan = 2024 Jan 2026 to 30 Jun 2026

Short Bowel Syndrome (SBS) · Intestinal Failure

Trial page ClinicalTrials.govUpdated 14 Jul 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.